Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Transl Oncol
.
2021 Sep;14(9):101156.
doi: 10.1016/j.tranon.2021.101156.
Epub 2021 Jun 17.
Authors
Firas Baidoun
1
,
Zahi Merjaneh
1
,
Fatma Abd-Elshahed Abd-Elhay
2
,
Mohamed Gomaa Kamel
3
Affiliations
1
Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44145, United States.
2
Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: fatma.abdelhai@s-mu.edu.eg.
3
Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: mohamedgomaa@s-mu.edu.eg.
PMID:
34147028
PMCID:
PMC8214216
DOI:
10.1016/j.tranon.2021.101156
No abstract available